Research Background

This trial explores a novel immunotherapy for patients with relapsed or refractory leukemia. Following CD19 CAR T-cell therapy, an increasing number of cases exhibit loss of CD19 expression, creating a need for alternative targets. CD22 is a widely expressed antigen in these patients, and CAR T cells targeting CD22 have been developed.

Study Design

In this Phase 1 study, autologous T cells are harvested, engineered to express a CD22-specific CAR, and reinfused. The primary objectives are to assess safety and manufacturability, confirming the ability to produce sufficient quantities of CAR T cells. Dose escalation and adverse event monitoring are central at this stage.

Differentiation and Expected Benefits

CD22 CAR T cells provide a new therapeutic option for CD19-negative leukemias. Existing treatments rely on chemotherapy or are limited to CD19 targeting, resulting in a high risk of relapse. Adding CD22 as a target enables an antigen-loss evasion strategy.

Clinical Status and Future Outlook

The trial is currently completed enrollment and is in a non‑recruiting status (ACTIVE_NOT_RECRUITING), having started in July 2017. If successful, it could expand into Phase 2/3 studies and serve as a platform applicable to other hematologic malignancies. Failure would necessitate reevaluation of target selection and the complexity of the manufacturing process.